echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Liver Cancer: Atezolizumab + Bevacizumab can significantly prolong the survival period of patients with advanced HCC in China!

    Liver Cancer: Atezolizumab + Bevacizumab can significantly prolong the survival period of patients with advanced HCC in China!

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In the IMbrave150 trial, compared with sorafenib, atezolizumab combined with bevacizumab can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients with unresectable hepatocellular carcinoma (HCC).
    )
    .


    This article reports the results of the efficacy and safety analysis of the subgroup of Chinese patients in this trial


    This article reports the results of the efficacy and safety analysis of the subgroup of Chinese patients in this trial


    IMbrave150 is a global, randomized, open-label Phase 3 trial that recruits unresectable HCC patients who have not undergone systemic treatment
    .


    The test patients were randomly (2:1) divided into two groups, and received intravenous atezolizumab (1200 mg) combined with bevacizumab (15 mg/kg) (1 time/3 weeks) or sorafenib, respectively (400 mg, 2 times/day) treatment until intolerable toxicity or loss of clinical significance


    From April 16, 2018 to April 8, 2019, a total of 194 Chinese patients were recruited (137 were in the overall study and 57 were in the extended study phase in China), of which 133 received atezolid Anti-combined bevacizumab treatment, 61 received sorafenib treatment
    .

    OS and PFS of the two groups

    OS and PFS of the two groups

    As of August 29, 2019, the median OS of the combination group and sorafenib group were not up to 11.
    4 months (adjusted hazard ratio [HR] 0.
    44; 95%CI 0.
    25-0.
    76); the median PFS was 5.
    7 vs 3.
    2 months (HR 0.
    60; 95% CI 0.
    40-0.
    90)
    .

    The median OS of the combination group and sorafenib group was not reached vs 11.
    4 months (adjusted hazard ratio [HR] 0.
    44; 95% CI 0.
    25-0.
    76); median PFS was 5.
    7 vs 3.
    2 months (HR 0.
    60) ; 95%CI 0.
    40-0.
    90)
    .


    The median OS of the combination group and sorafenib group was not reached vs 11.


    Adverse events

    Adverse events

    The incidence of grade 3-4 adverse events (AE) in the combination group and sorafenib group were 59.
    1% (78/132) and 46.
    6% (27/58), respectively
    .


    The most common grade 3-4 AE in the combination group was hypertension (15.


    In summary, compared with sorafenib single-agent therapy, atezolizumab combined with bevacizumab can also significantly prolong the PFS and OS of Chinese patients with advanced HCC , suggesting that this combined regimen may become an option for Chinese patients with unresectable HCC.


    Compared with sorafenib monotherapy, atezolizumab combined with bevacizumab can also significantly prolong the PFS and OS of patients with advanced HCC in China.


    Original source:

    Qin Shukui,Ren Zhenggang,Feng Yin-Hsun et al.


    Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.